Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
Image Source: Pixabay
Below are how each constituent stock performed last week, in descending order, and YTD, plus any recent news, commentary, and/or analysis for each company:
- atai Life Sciences (ATAI): UP 24.4% last week; UP 73.8% YTD
- Mind Medicine (MNMD): UP 17.0% last week; UP 200.5% YTD
- Compass Pathways (CMPS): UP 14.2% last week; UP 8.6% YTD
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest News, Commentary and/or Analysis:
- GH Research (GHRS): UP 4.5% last week; UP 92.1% YTD
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Latest News, Commentary and/or Analysis: None
- Incannex Healthcare (IXHL): DOWN 9.5% last week; DOWN 30.0% YTD
- is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Latest News, Commentary and/or Analysis: None
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 10.0%, on average, last week and are now UP 53.9% YTD.
More By This Author:
Tilray's Q3 Financials Disappoint: Stock Declines 31%
Hope Springs Eternal: Canadian Cannabis LPs Index Up 20% Last Week
American Cannabis MSO Stocks Index Flat Last Week; Up 51% YTD
Disclosure: None
This article has been composed with the exclusive application of the human intelligence (HI) of the author. No artificial intelligence (AI) technology has been deployed. ...
more